Morinaga & Co Ltd operates in the Candy & other confectionery products sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Morinaga & Co Ltd with three other
bakery and confectionary companies in Asia:
GlaxoSmithKline Consumer Healthcare Limited
sales of 47.82 billion Indian Rupees [US$670.92 million]
of which 100%
Nakamuraya Co., Ltd.
(38.74 billion Japanese Yen [US$354.51 million]
of which 76%
was Confectionery Business), and
Imuraya Group Company Limited
(45.11 billion Japanese Yen [US$412.74 million]
of which 87%
was Distribution Business).
Morinaga & Co Ltd reported sales of ¥205.37 billion (US$1.88 billion)
March of 2019.
a very small
increase of 0.2%
versus 2018, when the company's sales were ¥205.02 billion.
Sales at Morinaga & Co Ltd have increased during each of the previous five years
(and since 2014, sales have increased a total of 25%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
13.1% in 2019, from
¥511.00 million to ¥578.00 million.
Not all segments of Morinaga & Co Ltd experienced an increase in sales in 2019:
sales of Real Estate and Services fell 6.2% to ¥1.91 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).
Morinaga & Co Ltd also experienced decreases in sales in
Wholesale Food and Restaurant (down 0.3% to ¥6.66 billion)